ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Janku on Longitudinal Monitoring of BRAF V600E Mutation in Urinary Cell-Free DNA

Filip Janku, MD, PhD
Published: Monday, Jul 21, 2014

Filip Janku, MD, PhD, assistant professor, Department of Investigational Cancer Therapeutics, University of Texas, MD Anderson Cancer Center, discusses longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers. This study was presented at the 2014 ASCO Annual Meeting.

While BRAF mutation status changes over time, constantly biopsying patients is not feasible for a number of reasons. There remains a need for an alternative source of mutational analysis that can work over time.

The purpose of this study was to monitor the amount of BRAF mutation in a patient’s plasma and use it as a surrogate for response to therapy.

Filip Janku, MD, PhD, assistant professor, Department of Investigational Cancer Therapeutics, University of Texas, MD Anderson Cancer Center, discusses longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers. This study was presented at the 2014 ASCO Annual Meeting.

While BRAF mutation status changes over time, constantly biopsying patients is not feasible for a number of reasons. There remains a need for an alternative source of mutational analysis that can work over time.

The purpose of this study was to monitor the amount of BRAF mutation in a patient’s plasma and use it as a surrogate for response to therapy.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x